Advertisement
UK markets open in 5 hours 31 minutes

  • NIKKEI 225

    37,809.79
    -152.01 (-0.40%)
     

  • HANG SENG

    16,251.84
    0.00 (0.00%)
     

  • CRUDE OIL

    82.79
    +0.10 (+0.12%)
     

  • GOLD FUTURES

    2,384.40
    -4.00 (-0.17%)
     

  • DOW

    37,753.31
    -45.66 (-0.12%)
     

  • Bitcoin GBP

    49,471.24
    -1,873.63 (-3.65%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • NASDAQ Composite

    15,683.37
    -181.88 (-1.15%)
     

  • UK FTSE All Share

    4,273.02
    +12.61 (+0.30%)
     
Money:

5 ways to get help with childcare costs

Childcare is eye-wateringly expensive, here are some ways to save money

The allergic rhinitis segment held the largest share of the market in 2019. Moreover, the market for this segment is anticipated to grow at a significant CAGR during 2020–2027

ReportLinker
·2-min read

The Europe allergy immunotherapies market was valued at US$ 544. 14 million in 2019 and is projected to reach US$ 1,228. 14 million by 2027; it is expected to grow at a CAGR of 10. 8% during 2020–2027.

New York, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Europe Allergy Immunotherapies Market Forecast to 2027- COVID-19 Impact and Global Analysis - by Treatment ; Allergy Type ; Distribution Channel, and Country" - https://www.reportlinker.com/p05978838/?utm_source=GNW

The increasing prevalence of allergic disorders and technological advancements in sublingual dosage formulations are the key factors fueling the Europe allergy immunotherapies market growth.

Allergen immunotherapy is a medical treatment useful for environmental allergies, insect bite allergies, and asthma.Allergic disorders are among the most common problems examined by primary care physicians and paediatricians; according to the International Study of Asthma and Allergies in Childhood (ISAAC), 20% of children in the European countries suffer from hay fever.

The Europe allergy immunotherapy market is anticipated witness consistent growth in the coming years owing to increasing government expenditures on the healthcare sector for research and development in European countries. Additionally, high awareness regarding allergies and treatments available for the same, and increasing need for advanced treatments further pose lucrative growth opportunities to the market players.

The Europe allergy immunotherapies market, based on treatment, is segmented into subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT).In 2019, the SCIT segment held a larger share of the market.

However, the SLIT segment is expected to register a higher CAGR in the market during the forecast period.The Europe allergy immunotherapies market, based on allergy type, was segmented into allergic rhinitis, asthma, food allergy, venom allergy, and others.

The allergic rhinitis segment held the largest share of the market in 2019. Moreover, the market for this segment is anticipated to grow at a significant CAGR during 2020–2027.

The Europe allergy immunotherapies market, based on distribution channel, is segmented into, hospital pharmacy, retail pharmacy, and online pharmacy.In 2019, the hospital pharmacy segment held the largest share of the market.

Moreover, the same segment is expected to register a higher CAGR in the market during the forecast period.

Some of the major primary and secondary sources referred to while preparing this report on the Europe allergy immunotherapies market are Celsion Corporation, European and Developing Countries Clinical Trials Partnership (EDCTP), EuropaBio, European Federation of Biotechnology (EFB), and European Academy of Allergy and Clinical Immunology.
Read the full report: https://www.reportlinker.com/p05978838/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001